Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 2/2000

01-01-2000

Single agent epirubicin as first line chemotherapy for metastatic breast cancer patients

Authors: Andrea Michelotti, Marco Venturini, Carmelo Tibaldi, Carmelo Bengala, Luigi Gallo, Flavio Carnino, Lucia Del Mastro, Rita Lionetto, Elda Montanaro, Riccardo Rosso, Pierfranco Conte

Published in: Breast Cancer Research and Treatment | Issue 2/2000

Login to get access
Metadata
Title
Single agent epirubicin as first line chemotherapy for metastatic breast cancer patients
Authors
Andrea Michelotti
Marco Venturini
Carmelo Tibaldi
Carmelo Bengala
Luigi Gallo
Flavio Carnino
Lucia Del Mastro
Rita Lionetto
Elda Montanaro
Riccardo Rosso
Pierfranco Conte
Publication date
01-01-2000
Publisher
Kluwer Academic Publishers
Published in
Breast Cancer Research and Treatment / Issue 2/2000
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1023/A:1006394801389

Other articles of this Issue 2/2000

Breast Cancer Research and Treatment 2/2000 Go to the issue

Instructions for Authors

Breast cancer research and treatment

OriginalPaper

The prognostic value of proliferation indices: a study with in vivo bromodeoxyuridine and Ki-67

OriginalPaper

Lipid peroxidation, free radical production and antioxidant status in breast cancer

OriginalPaper

Prognostic relavance of cerbB2 expression following neoadjuvant chemotherapy in patients in a randomised trial of neoadjuvant versus adjuvant chemoendocrine therapy

OriginalPaper

Shorter CAG repeat length in the androgen receptor gene is associated with more aggressive forms of breast cancer

OriginalPaper

Surgical treatment of hepatic metastases from breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits